경보제약, 88억 규모 원료의약품 공급계약 해지

This termination highlights the increasing volatility and regulatory risks in the Chinese pharmaceutical market, which can significantly impact Korean exporters. The unilateral cancellation reflects shifting local policies and price pressures that necessitate a strategic diversification of global supply chains for domestic manufacturers.